quinta-feira, 22 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 3, 2025

NTT Scientists Contribute Fifteen Research Papers to NeurIPS 2025

View original at finance.yahoo.com
NTT Scientists Contribute Fifteen Research Papers to NeurIPS 2025 NTT Research, NTT, Inc. and NTT DATA showcase foundational theory, system-level advances and enterprise-grade innovations across five major themes at premier AI conference News Highlights: NTT Research, NTT, Inc…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI is becoming ubiquitous, but how these computational engines actually work remains—to a surprising degree—a mystery, which is why our scientists keep probing with fundamental questions

    80% confidence
  • Standard SAEs architectures embed implicit geometric assumptions that not only reveal concepts inside models but also shape what concepts can be discovered

    80% confidence
  • With the EU AI Act mandating watermarking, the topic has become increasingly urgent, and even state-of-the-art watermarking schemes can be reverse engineered, revealing significant risks for enterprises

    80% confidence
  • Researchers must keep pace with operational challenges in AI development

    80% confidence
  • Understanding training dynamics in in-context learning may enable engineering reliable ICL behavior

    80% confidence
  • The watermarking vulnerability findings expose a foundational vulnerability in today's AI trust and traceability mechanisms

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,426 documentos-fonte arquivados
Consulte estes dados → isubstrate.com